ANN ARBOR, Mich., Feb. 16, 2012 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic
DNA-based therapeutics and innovative disease-modifying medicines
for serious illnesses, announced today that it
received approval at yesterday's special meeting of
stockholders to change its corporate name to Synthetic Biologics,
Inc. It is expected that the Company's shares will start trading
under its new name and stock ticker symbol, "SYN", effective as of
market open today, Thursday, February 16,
2012. Synthetic Biologics' common stock has been assigned a
new CUSIP number of 87163U102 in connection with the name change.
Outstanding stock certificates are not affected by the name change
and will not need to be exchanged.
Following the special meeting, the Company filed an amendment to
its Articles of Incorporation with the Nevada Secretary of State to effect the name
change.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the
development of synthetic DNA-based therapeutics and innovative
disease-modifying medicines for serious illnesses. Synthetic
Biologics is developing, or has partnered the development of,
product candidates to treat pulmonary arterial hypertension,
relapses in multiple sclerosis, cognitive dysfunction in multiple
sclerosis, fibromyalgia and amyotrophic lateral sclerosis (ALS).
For more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.